HER2 displayed on the surfaces of breast cancer exosomes has been shown to bind and sequester the therapeutic monoclonal antibody Herceptin®, thereby allowing continued tumor cell proliferation [101]. This evidence concerns the gene ERBB2 and breast carcinoma.